Anemia remains ubiquitous among patients with cancer. Despite a preponderance of
positive data on the use of erythropoietic stimulating agents (ESAs) and intravenous (IV) …

Coadministration of intravenous (IV) iron improves responses to erythropoiesis-stimulating
agents (ESAs) in the treatment of cancer-associated (CAA) and chemotherapy-induced …

Despite increasing use of targeted therapies to treat cancer, anemia remains a common
complication of cancer therapy. Physician concerns about the safety of intravenous (IV) iron …

Anemia is prevalent in 30% to 90% of patients with cancer. Anemia can be corrected
through either treating the underlying cause or providing supportive care through transfusion …

Anemia has myriad causes. In patients with cancer, the chief culprits are direct myelotoxicity
from antineoplastic drugs and cytokine-mediated inhibition of erythropoiesis. 1 A host of …

To help mark the 10 th volume of JNCCN, I was asked to comment on the evolution of
anemia management for patients with cancer over the past decade. I joined the panel for the …

TO THE EDITOR: Auerbach et al1 report on a randomized trial of iron supplement in cancer
patients with chemotherapy-related anemia receiving recombinant human erythropoietin …

Cancer‐related anemia (CRA) is due to multiple etiologies, including chemotherapy‐
induced myelosuppression, blood loss, functional iron deficiency, erythropoietin deficiency …

Before 1989, when epoetin was introduced for dialysisassociated anemia, the use of
intravenous (IV) iron in the United States was typically avoided. Shortly thereafter, it was …

Management of anemia in patients with cancer presents challenges from clinical,
operational, and economic perspectives. Clinically, anemia in these patients may result from …